Assessing physicians’ preferences on skin cancer treatment in Europe

摘要: Summary Background  A wide variety of both surgical and nonsurgical therapies is currently available for patients with skin cancer. Objectives  This part the EPIDERM (European Prevention Initiative Dermatological Malignancies) project aimed at evaluation treatment preferences cancer in eight countries European Union. Methods  multicentre hospital-based case–control study was carried out dermatology departments Finland, Germany, Greece, Italy, Malta, Poland, Scotland Spain. Patients (basal cell carcinoma, actinic keratosis, squamous cutaneous malignant melanoma Bowen disease) were consecutively enrolled between July 2008 2010. Information on variables (sex, age, country, tumour type, anatomical location treatment) obtained from questionnaires designed by project. Results  In total, 1708 included. Surgery first option 76·5% (P = 0·001). Actinic keratosis only type which more frequent than surgery (91·4%). Tumours head less likely to be surgically excised those other locations (odds ratio 0·25, P = 0·001). Simple excision or curettage most common procedure (65·4%), followed graft flaps (22·4%). Cryotherapy (52·4%), imiquimod (18·0%), photodynamic therapy (PDT; 12·0%), 5-fluorouracil (5-FU; 5·7%), diclofenac hyaluronic acid (4·0%). Conclusions  remains first-choice cancer. Regarding treatments, conservative treatments (imiquimod, 5-FU, PDT gel) have not yet exceeded use ablative options such as cryotherapy despite their accepted benefit treating field cancerization.